NPPB

1. Semaglutide decreases NPPB in humans.

   “After 104 weeks of treatment, 5 of those were reduced significantly (Fig): cardiac stress markers (NPPB), matrix remodeling enzymes (TNFRSF11B), growth factors (GDF15) and immune/inflammatory mediators (TREM1, CCL15).”

   Human trialin patients with ASCVD and obesity without diabetes2.4 mg104 weeks

   Exploring Semaglutide's Effect on the ASCVD-Related Proteomic Signature and Their Prediction of MACE in SELECT

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

More on Semaglutide

1. NPPB predicts major adverse cardiovascular events in humans (HR 1.2-1.6, p<0.05).

   “At BL, 8 of the 70 proteins tested (NPPB, WFDC2, GDF15, TREM1, CCL15, MCTS1, TNFRSF11B, MANEA) were prognostic for MACE (HR 1.2-1.6, p<0.05).”

   Human trialbaseline in patients with ASCVD and obesity without diabetes

   Exploring Semaglutide's Effect on the ASCVD-Related Proteomic Signature and Their Prediction of MACE in SELECT

   ADA Scientific Sessions 2026 abstract·5 Jun 2026